Price Crosses Moving Average
|Bid||51.30 x 1200|
|Ask||52.75 x 1200|
|Day's Range||50.91 - 51.54|
|52 Week Range||34.98 - 54.17|
|Beta (5Y Monthly)||0.80|
|PE Ratio (TTM)||86.92|
|Earnings Date||Jul 25, 2023 - Jul 31, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||58.40|
Subscribe to Yahoo Finance Plus to view Fair Value for BSXLearn more
Catalent's (CTLT) expansion of its OneBio Suite across multiple biologic therapies is expected to aid customers in leveraging its end-to-end capabilities in these areas.
In this article, we discuss 15 best healthcare stocks billionaires are loading up on. You can skip our detailed discussion on the healthcare sector and its performance, and go directly to read 5 Healthcare Stocks Billionaires Are Loading Up On. The healthcare sector in the US is a multifaceted industry that plays a crucial role […]
Inari Medical's (NARI) latest launches are expected to serve a wider patient pool by improving treatment options.
Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.
Masimo's (MASI) Radius VSM is expected to equip any hospital bed with comprehensive monitoring and offer more personalized care without additional bedside equipment.
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2024.
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.
Right now, the global healthcare industry faces a worldwide staffing shortage that is roundly expected to worsen.
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But the truth is...
PacBio's (PACB) product development activities raise optimism about the stock.
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both segments.
Investors remain optimistic about DaVita (DVA) due to the strength of its DaVita Kidney Care.
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
Veeva Systems (VEEV) expands its partnership with Lotus Clinical to accelerate clinical trials.
Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.
Here is how Augmedix, Inc. (AUGX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Boston Scientific Corporation (NYSE: BSX) announced today that its Series A 5.50% Mandatory Convertible Preferred Stock (the preferred stock) will automatically convert into shares of the company's common stock on June 1, 2023. As previously disclosed, holders of record at the close of business on May 15, 2023 will separately receive a final quarterly cash dividend of $1.375 per share of preferred stock, payable on June 1, 2023. Following the conversion of the preferred stock, there will be no o
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.
NORTHAMPTON, MA / ACCESSWIRE / May 30, 2023 / Boston Scientific One in five American adults has a diagnosable mental health condition. Yet all too often, our friends, co-workers, neighbors and family members suffer emotionally and either don't recognize ...
Boston Scientific's (NYSE:BSX) stock is up by 9.1% over the past three months. However, the company's financials look a...
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid the CDMO to modernize its operations and streamline its quality processes globally.
Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.
Boston Scientific Corporation (NYSE: BSX) is terminating its $230 million plan to buy a majority stake in M.I. Tech, a publicly traded Korean manufacturer and distributor of medical devices for endoscopic and urologic procedures. The MedTech giant announced acquiring the Korean company in June last year at KRW 14,500 per share, representing KRW 291.2 billion or approximately $230 million. Also Read: Boston Scientific Clocks Strong Q1 Earnings As Elective Surgeries Recover, Boosts FY23 Outlook. “